CCEL

Cryo-Cell International, Inc. (CCEL) 10Y Growth Potential Analysis (2026)

Invetso Score: 3.9/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 4.8 (Moderate)

Revenue growth capacity is difficult to evidence from the provided metrics because five-year CAGR data are unavailable, limiting proof of durable compounding versus peers.

Low capex intensity suggests limited reinvestment needs, which can support incremental scaling, but it does not by itself demonstrate stronger expansion than peers.

Negative TTM ROIC indicates current capital deployment is not yet generating attractive incremental returns, reducing confidence that reinvested capital will compound revenue efficiently.

The absence of disclosed segmentation concentration metrics prevents confirming whether the business can broaden revenue streams faster than more diversified peers.

Market Tailwinds

Score:

No post-2025 filing evidence is provided for demand acceleration, so long-term tailwinds cannot be verified beyond the company’s current operating footprint.

The available data show no clear structural demand catalyst that would distinguish CCEL from peers with more visible multi-year growth runways.

Negative profitability and weak coverage metrics imply external tailwinds are not yet translating into durable revenue expansion, limiting peer-relative growth visibility.

Without segment or geographic detail, it is not possible to confirm whether CCEL benefits from broader market expansion than similarly sized competitors.

Scalability Expansion

Score:

Very low capex-to-revenue suggests a potentially asset-light model, but the metrics do not prove that this structure scales revenue faster than peers.

Negative interest coverage and high net debt to EBITDA indicate balance-sheet constraints that can restrict reinvestment capacity and slow expansion.

The negative TTM ROIC implies that additional growth capital may not currently earn sufficient returns, weakening evidence of scalable compounding.

Because peer-comparable operating leverage data are absent, the company’s ability to expand margins and revenue simultaneously remains unproven.

Constraints Limitations

Score:

Net debt to EBITDA of 14.6x is materially elevated, and such leverage can constrain strategic flexibility and limit long-term growth investment versus peers.

Interest coverage is negative, which signals current earnings are insufficient to service debt and materially impairs scalable reinvestment capacity.

Negative ROIC suggests the business is not currently converting capital into value-creating growth, which structurally caps compounding potential.

The lack of demonstrated multi-year growth metrics leaves CCEL looking more constrained than peers with proven revenue CAGR and stronger capital efficiency.

Overall Score

Score:

CCEL’s long-term growth capacity appears structurally constrained by very high leverage, negative interest coverage, and negative ROIC, while the provided data do not show proven multi-year revenue compounding versus peers.

Score Driver: High Leverage

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Cryo-Cell International, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →